This approach has become increasingly pertinent due to the growing use of NACT, which, although initially reserved for locally advanced breast cancers (LABCs) [3], is now recommended as the preferred treatment for HER2-positive (HER2 +) and triple-negative breast cancer (TNBC) [25], [26], even in early-stage cases where tumors are larger than 1.5 cm, as per guidelines from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN). This evidence concerns the gene ERBB2 and breast carcinoma.